Trump’s Psychedelics Executive Order: Reactions From Across the Field and Beyond
- Advocates Rejoice
- Ibogaine’s Moment, DemeRx’s IND Clearance
- Industry Responds
- Researchers Unclear on Benefits; ARPA-H Allots Funds
- Politicisation and Its Discontents
- What Comes Next
On Saturday, President Trump signed an executive order that set out several measures geared towards accelerating psychedelic research and access. We covered the news via an article and video on the day.
A poll of Psychedelic Alpha readers (n=196) suggested a largely positive reaction:
Here, we dive deeper into reactions from across the psychedelics field and beyond…
Join Today
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and research.
- Regular Bulletins featuring news, analysis, and research
- Articles and deep dives across psychedelic drug development, policy, and research
- Exclusive interviews with researchers, executives, and policymakers
- Bespoke resources and tools including the Psychedelic Bill Tracker
- Quarterly video briefings and slide decks
Already a member?
Sign In